🚀 BREAKING TECH NEWS, UPDATED DAILY

Controversial NIH Director Also Takes Helm at CDC Amid RFK Jr.

Jay Bhattacharya, the controversial NIH Director, has been appointed acting CDC Director, marking an unusual dual role amidst Health Secretary Robert F. Kennedy Jr.'s leadership shake-up. Critics express alarm over Bhattacharya's perceived lack of leadership and history of endorsing anti-vaccine policies, fearing further destabilization of public health agencies and a rubber-stamping of unscientific agendas.

PublishedFebruary 22, 2026
Reading Time3 min
SourceArs Technica
Controversial NIH Director Also Takes Helm at CDC Amid RFK Jr.

Controversial NIH Director Also Takes Helm at CDC Amid RFK Jr. Shake-Up

Key takeaways

  • Jay Bhattacharya, the current Director of the National Institutes of Health (NIH), has been appointed acting Director of the Centers for Disease Control and Prevention (CDC).
  • This unusual dual role occurs amidst significant leadership changes within the Department of Health and Human Services (HHS) under anti-vaccine Secretary Robert F. Kennedy Jr.
  • Bhattacharya's leadership at NIH has been criticized for defunding research, numerous vacancies, and a perceived hands-off management style.
  • Public health experts express concern that he will continue to rubber-stamp Kennedy's anti-vaccine agenda, as he previously approved drastic cuts to childhood vaccine recommendations.
  • His tenure as acting CDC director is temporary, legally limited to 210 days, with a deadline for a permanent nomination approaching on March 25.

What happened

Jay Bhattacharya, currently serving as the Director of the National Institutes of Health (NIH), has additionally assumed the role of acting Director for the Centers for Disease Control and Prevention (CDC). This is an uncommon arrangement that has immediately drawn sharp criticism from scientific researchers and public health experts. The appointment is part of a broader leadership restructuring within the Department of Health and Human Services (HHS), spearheaded by anti-vaccine Health Secretary Robert F. Kennedy Jr. Bhattacharya is the third leader for the CDC under Secretary Kennedy's administration, highlighting a period of significant turnover for the public health agency.

Why it matters

This dual appointment is highly significant due to the ongoing turmoil within US public health agencies and Bhattacharya's controversial record at the NIH. Critics argue that his perceived lack of hands-on leadership at NIH, which has seen hundreds of millions of dollars in research grants frozen or terminated and an unprecedented number of vacancies, makes him ill-suited to oversee two vital institutions simultaneously. The appointment raises concerns about the stability and scientific independence of both the NIH and CDC. Experts fear that Bhattacharya will further facilitate Secretary Kennedy's anti-vaccine agenda, potentially undermining evidence-based public health practices and contributing to the resurgence of preventable diseases, such as measles.

Key details / context

The CDC has experienced considerable instability under Secretary Kennedy's leadership. Susan Monarez, a microbiologist and the first Senate-confirmed CDC director under Kennedy, was ousted within a month for allegedly refusing to endorse changes to vaccine recommendations proposed by Kennedy's anti-vaccine advisors. Her successor, Jim O'Neill, a Silicon Valley investor and ally of Peter Thiel, then served as acting director and approved a dramatic overhaul of the CDC's childhood vaccine recommendations. O'Neill is reportedly now slated for nomination to lead the National Science Foundation.

While Bhattacharya, a health economist with a medical degree, possesses more relevant qualifications than O'Neill, his leadership at NIH has been contentious. A recent Senate report revealed that under his directorship, the NIH halted or froze $561 million in grants for research into the four leading causes of death in America. At least 304 clinical trials were defunded. Additionally, 16 of the NIH's 27 institutes and centers currently lack directors, marking an unprecedented number of vacancies. Bhattacharya is known for delegating most of his responsibilities to other officials and for frequent public interviews, earning him the moniker

#NIH#CDC#Robert F. Kennedy Jr.#RFK Jr.#Jay Bhattacharya#Public HealthMore

Related articles

Ars TechnicaFeb 25

US Solar Power Surges 35%, Overtakes Hydro on National Grid

In 2025, US solar power generation achieved a significant milestone, growing by 35% to surpass hydroelectricity for the first time. Despite this renewable surge, overall electricity demand increased by 2.8%, leading to an unexpected 13% rise in coal consumption due to complex market dynamics affecting natural gas. Looking ahead, 2026 is projected to see substantial additions in solar and wind capacity, aiming to further integrate renewables into the national grid.

Washington Post TechnologyFeb 25

policy: Most teens believe their peers are using AI to cheat in

A Pew survey, reported by Washington Post Technology, reveals that over 10% of U.S. teens use AI for emotional support or advice. The study also highlights that teens are significantly more hopeful about artificial intelligence technology compared to adults, underscoring distinct generational perspectives on AI's role and potential impact.

VentureBeatFeb 25

KiloClaw: Deploy OpenClaw Agents in 60 Seconds with Managed AI

Kilo has launched KiloClaw, a fully managed service designed to deploy OpenClaw agents into production in under 60 seconds. This platform removes infrastructure complexities, provides secure and always-on hosting, and integrates with Kilo Gateway for access to over 500 AI models. Kilo also introduced PinchBench, an open-source benchmark for agentic tasks, aiming to democratize AI agent deployment for a wider audience.

The Next WebFeb 24

startups: The EU’s strategic rebalancing of research partnerships

The EU's €93 billion Horizon Europe program has undergone a significant transformation in 2026, largely blocking Chinese organizations from receiving EU funding in critical tech areas like AI and semiconductors. This strategic shift is driven by concerns over research security and intellectual property, reflecting Europe's evolving approach to global scientific partnerships amidst geopolitical complexities.

GeekWireFeb 23

GeekWire's Top Stories: Feb. 15, 2026 Week in Review

GeekWire's top stories for the week of Feb. 15, 2026, highlight Microsoft's new RTO policy and leadership changes at Xbox and Remitly. Washington state is setting new terms for data centers, while Seattle-area startups Temporal and Duckbill secured significant funding rounds. The tech community also paid tribute to desktop publishing pioneer Paul Brainerd.

Ars TechnicaFeb 23

Unpacking the Risks of Commercial Genetic Testing

Have we leapt into commercial genetic testing without understanding it?\ \ Key takeaways\ * A new book,

Continue reading on the source

This article was summarized and curated from Ars Technica.

View Original Story